Media Advisory: GSK Recalls Two Lots of Migraine Medication: IMITREX Injection

(firmenpresse) - OTTAWA, ONTARIO -- (Marketwired) -- 11/01/13 -- The issue:

GlaxoSmithKline Inc., in consultation with Health Canada, is voluntarily recalling two lots of "IMITREX Injection", a migraine medication packaged in pre-filled syringes with an accompanying sterile needle for injection. The needles come with plastic shields that are designed to keep them free of contamination. Needles in the affected lots may be protruding through the needle shield.

The protruding needle is no longer sterile and as such, there is a potential risk of infection to consumers when using the product.

Who is affected: Consumers who have used or are using any product from the two affected lots (see below).

What consumers should do:

- Patients who have IMITREX injection from the affected lots should not use the product, and should return it to their pharmacist.

- If you have used IMITREX injection in the past three months, contact your healthcare professional.

- Report any adverse events using this product to .

- Contact GSK Inc. at 1-800-387-7374for more information about returning the product.

What Health Canada is doing:

Health Canada is monitoring the recall of "IMITREX Injection" by GSK.

Products affected:

For more information:

Consumers and health professionals wanting more information about this advisory from Health Canada can contact the Public Enquiries Line at 613-957-2991, or toll free at 1-866-225-0709.

Media enquiries related to this Advisory should be directed to Health Canada Media Relations at 613-957-2983.

How to report side effects to health products:

- Call toll-free at 1-866-234-2345

- Visit MedEffect Canada's web page on for information on how to report online, by mail or by fax.

Stay connected with Health Canada and receive the latest advisories and product recalls using tools.

Egalement disponible en francais



Contacts:
Media Inquiries:
Health Canada
613-957-2983

Public Inquiries:
613-957-2991
1-866-225-0709

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: Marketwired
Datum: 01.11.2013 - 21:52 Uhr
Sprache: Deutsch
News-ID 311927
Anzahl Zeichen: 0

contact information:
Town:

OTTAWA, ONTARIO

Kategorie:

Government & Administration

Diese Pressemitteilung wurde bisher 281 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Media Advisory: GSK Recalls Two Lots of Migraine Medication: IMITREX Injection"
steht unter der journalistisch-redaktionellen Verantwortung von

Health Canada (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Media Advisory: Health Canada ...

OTTAWA, ONTARIO -- (Marketwired) -- 12/16/13 -- Parliamentary Secretary Eve Adams, on behalf of Rona Ambrose, Minister of Health, along with a toy safety expert from Health Canada`s Consumer Product Safety Division, will hold a demonstration on sma ...

Consumer Product Alert: Health Canada Urges Parents to Safeguard Children from C ...

OTTAWA, ONTARIO -- (Marketwired) -- 12/11/13 -- Issue:Health Canada is urging parents and caregivers to safeguard children against the strangulation hazard posed by products with cords. While exploring their natural environment, children can become ...

Use a Digital Food Thermometer for Safe Cooking ...

OTTAWA, ONTARIO -- (Marketwired) -- 12/10/13 -- The only reliable way to make sure that meat, poultry, fish and seafood dishes reach safe internal cooking temperatures before serving is to use a digital food thermometer.While we often look for other ...

Alle Meldungen von Health Canada